Revolutionizing Treatment Approaches for Cardiomyopathy Among Methamphetamine Users
Cardiomyopathy cases linked to methamphetamine use have surged in the American West, according to the most recent 13-year hospital admission data. An analysis of the National Inpatient Sample (NIS) revealed a staggering 231% increase in methamphetamine-related cardiomyopathy admissions from 2008 to 2020, compared to just a 12% increase in overall heart failure admissions during the same period. This data was shared by Mohammad Bhuiyan, PhD, and his team from Louisiana State University Health Sciences Center at Shreveport.
Geographical and social disparities were evident within methamphetamine-related cardiomyopathy admissions, with significant increases seen in various demographics:
By gender: a 345% rise in admissions for men and a 122% increase for women
By race: admissions surged by 271% for white individuals, 254% for Black individuals, 565% for Hispanic individuals, and a substantial 645% for Asian groups
By region: a substantial 530% increase in the West and a 200% increase in southern states, while the Northeast remained relatively stable
According to Bhuiyan’s team, cardiomyopathy related to methamphetamine use primarily affects middle-aged men, particularly concentrated in the western region of the United States.
Methamphetamine, colloquially known as “meth,” is a potent stimulant drug with highly addictive properties. While some forms are prescribed for medical purposes like obesity and attention deficit-hyperactivity disorder, illicit versions are derived from over-the-counter drugs. The CDC estimates that approximately 1.6 million American adults reported using methamphetamine in the years 2015-2018.
The drug has well-established connections to cardiovascular ailments, including cardiomyopathy, heart failure, pulmonary hypertension, and coronary artery disease.
Noted cardiologist Nisha Parikh, MD, MPH, from the University of California San Francisco Health, and her colleagues, emphasize the urgent need for action to combat the escalating epidemic of methamphetamine-related cardiomyopathy. They stress the importance of acknowledging and addressing biases within the healthcare system towards patients with substance use disorders.
In a supplementary editorial, the trio expands on previous research indicating a rapid rise in methamphetamine-associated heart failure hospitalizations, particularly among men, younger individuals, and lower socioeconomic populations between 2002 and 2014. They highlight the disproportionate impact on people of Hispanic, Native American, and Asian/Pacific Islander descent in this context.
Parikh and her colleagues call for targeted interventions, such as the development of pharmacotherapy for methamphetamine use disorder (MAUD), to address the unique needs of this vulnerable patient population. They also emphasize the importance of recognizing the diverse health and life priorities among individuals struggling with methamphetamine use.
In conclusion, the escalating crisis of methamphetamine-induced cardiomyopathy calls for innovative and targeted approaches to effectively address this growing public health challenge.